Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Oesophageal Cancer
Conditions
Keywords
Nivolumab, Atezolizumab, Pembrolizumab, Extended dosing interval
Brief summary
This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab, atezolizumab or pembrolizumab in advanced/unresectable gastric/gastroesophageal junction/oesphageal adenocarcinomas with PDL1 CPS ≥5%, hepatocellular carcinoma andnon-small cell lung cancer with PDL1 TPS≥50% with no prior treatment. The investigators hypothesize that nivolumab, pembrolizumab and atezolizumab can be used efficiently at extended dosing intervals, compared to their approved labels with comparable clinical outcome.
Detailed description
This study aims to assess the noninferiority of progression free survival of standard dosing compared to extended dosing interval of nivolumab, pembrolizumab and atezolizumab in advanced/unresectable gastric/gastroesophageal junction/oesphageal adenocarcinomas with PDL1 CPS ≥5%, hepatocellular carcinoma, and non-small cell lung cancer with PDL1 TPS≥50%. Secondary Objective * To investigate the safety, overall survival (OS) of ICI at extended dosing interval of the standard versus extended dosing interval groups. * To investigate the pharmacokinetics (PK) of nivolumab, atezolizumab or pembrolizumab.
Interventions
DRUGExtended Dosing Interval - A
Nivolumab 360mg 6 weekly (up to 2 years) + XELOX Nivolumab 240mg 4 weekly (up to 2 years) + FOLFOX
DRUGExtended Dosing Interval - B
Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)
DRUGExtended Dosing Interval - C
Pembrolizumab 200mg 6 weekly (up to 2 years)
DRUGStandard of Care - A
Nivolumab 360mg 3 weekly (up to 2 years) + XELOX Nivolumab 240mg 2 weekly (up to 2 years) + FOLFOX
DRUGStandard of Care - B
Bevacizumab + Atezolizumab 1200mg 3 weekly (up to 2 years)
DRUGStandard of Care - C
Pembrolizumab 200mg 3 weekly (up to 2 years)
Sponsors
National University Hospital, Singapore
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study is a prospective, open label, multi-centre phase 2 trial
Eligibility
Sex/Gender
ALL
Age
21 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Provision of informed consent prior to any study-specific procedure 2. Patients with one of the following: * Cohort A: Previously untreated locally advanced/metastatic HER2 -ve gastric/gastroesophageal junction/esophageal (PDL1 CPS ≥5% adenocarcinomas not amenable to curative surgery or radiotherapy who are above to begin platinum double and nivolumab. * Cohort B: Previously untreated locally advanced/metastatic Child's A hepatocellular carcinoma not amenable to curative surgery or radiotherapy who are above to begin atezolizumab and bevacizumab. * Cohort C: Previously untreated locally advanced/metastatic lung adenocarcinoma (PDL1 TPS≥50%, EGFR/ALK wildtype) not amenable to curative surgery or radiotherapy who are above to begin pembrolizumab monotherapy 3. Measurable disease per RECIST 1.1 criteria 4. ECOG Performance status is 0-2 5. Normal organ and bone marrow function measured within 28 days before the study as defined below: * Haemoglobin ≥ 8.0 g/dL and no blood transfusions in the 28 days prior to entry * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L * No features suggestive of MDS/AML on peripheral blood smear * White blood cells (WBC) \> 3x10\^9/L * Platelet count ≥ 100 x 10\^9/L * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) * AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN * Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN) 6. A life expectancy ≥ 12 weeks in all patients. 7. Females in childbearing age should be using adequate contraceptive measures, should not be breastfeeding and their pregnancy test prior to the start of treatment must be negative. Evidence of non-child-bearing potential is fulfilled by one of the following criteria at screening: 8. The post-menopausal period defined as age ≥50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments 9. Women \<50 years old they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range. 10. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not a tubal ligatio 11. Male patients should be willing to use barrier contraception 12. The patient is willing to comply with the protocol during the study including undergoing treatment and scheduled visits and examinations including follow up. 13. At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and is considered suitable for accurate repeated measurements
Exclusion criteria
1. Patients who have previously received immune checkpoint inhibitors or investigational monoclonal antibody therapy. 2. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years 3. Unstable spinal cord compression/brain metastases unless asymptomatic and not requiring steroids for at least 2 weeks prior to the start of study treatment. For patients with brain metastases, gamma knife or stereotactic brain surgery is allowed prior to study treatment. 4. Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. Minor surgery is allowed. 5. Severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which based on investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or having active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required. 6. Autoimmune disorders 7. Males and females of reproductive potential who are not using an effective method of contraception and females who are pregnant or breastfeeding or have a positive serum pregnancy test prior to study entry 8. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements 9. Previous allogeneic bone marrow transplant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | Up to 2 years | PFS is defined as the time from date of first dosing until the date of objective disease progression as defined by Response Evaluation Criteria in Solid Tumor (RECIST 1.1) or death (by any cause in the absence of progression). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participant with treatment related haematological and non-haematological toxicities | Up to 2 years | As defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 |
| Objective response rate | Up to 2 years | Percentage of patients who have at least one confirmed response of 'complete response' or 'partial response' as defined by Response Evaluation Criteria in Solid Tumor (RECIST 1.1), that is confirmed at least 4 weeks later |
| Duration of Response | Up to 2 years | Duration of response will be defined as the time from the date of first documented response, that is subsequently confirmed until the date of documented progression or death in the absence of disease progression, the end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. |
| Disease control rate | Up to 2 years | Disease control rate is defined as the proportion of patients with a best overall response of CR = complete response, PR = partial response, or SD = stable disease, as defined by Response Evaluation Criteria in Solid Tumor (RECIST 1.1) |
| Overall survival | Up to 2 years | Overall survival will be assessed based on the date of first dose and survival status at the time of analysis. |
Countries
Singapore
Contacts
Primary ContactWei Peng Yong
Outcome results
None listed